PLX

SEC source: 0001104659-23-101237 · tm2326155d2_4.xml · derivative · entry 1

Forster Eliot · CIK 0001831558 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,715

Underlying: Common Stock · 85,715 shares

Expires 2033-09-14

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-23-093073 · tm2324046-4_4seq1.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,885,458

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-23-093070 · tm2324046-3_4seq1.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 570,000

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-23-093069 · tm2324046-2_4seq1.xml · derivative · entry 2

Hayon Yael · CIK 0001817121 · VP, Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,115

Underlying: Common Stock · 35,115 shares

Expires 2033-08-15

F3 · derivative.exercise_date: The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F4 · balance_after: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032.

SEC source: 0001104659-23-093069 · tm2324046-2_4seq1.xml · nonDerivative · entry 1

Hayon Yael · CIK 0001817121 · VP, Research & Development

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 35,115

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the "Plan"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-23-093066 · tm2324046-1_4seq1.xml · nonDerivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 200,817

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-23-001495 · tm232297-1_4seq1.xml · nonDerivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $1.430 to $1.405 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-22-098950 · tm2225460-7_4seq1.xml · derivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029.

SEC source: 0001104659-22-098956 · tm2225460-10_4seq1.xml · derivative · entry 1

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032.

SEC source: 0001104659-22-098953 · tm2225460-9_4seq1.xml · derivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,000

Underlying: Common Stock · 340,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030.

SEC source: 0001104659-22-098951 · tm2225460-8_4seq1.xml · derivative · entry 1

Hayon Yael · CIK 0001817121 · VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030.

SEC source: 0001104659-22-098949 · tm2225460-6_4seq1.xml · derivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029.

SEC source: 0001104659-22-098948 · tm2225460-5_4seq1.xml · derivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030.

SEC source: 0001104659-22-098947 · tm2225460-4_4seq1.xml · derivative · entry 1

Bronfeld Zeev · CIK 0001298522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant.

F2 · balance_after: Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030.

SEC source: 0001104659-22-098945 · tm2225460-3_4seq1.xml · derivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030.

SEC source: 0001104659-22-098944 · tm2225460-2_4seq1.xml · derivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030.

SEC source: 0001104659-22-098941 · tm2225460-1_4seq1.xml · derivative · entry 1

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-09-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030.

SEC source: 0001104659-22-077380 · tm2220369-1_4seq1.xml · derivative · entry 1

Ben Zvi Shmuel · CIK 0001935668 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-22-045488 · tm2212654-1_4seq1.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

F1 · ownership.direct: The reporting person holds the shares in an account with his spouse as joint tenants.

SEC source: 0001104659-22-028159 · tm227910-2_4seq1.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 368,097

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-22-028157 · tm227910-1_4seq1.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,085,458

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-21-076488 · tm2118431-1_4seq1.xml · nonDerivative · entry 2

Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner

Oren Dan · CIK 0001636701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,637,314

F3 · price: The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.

F4 · price: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F1 · acquired: Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.

SEC source: 0001104659-21-076488 · tm2118431-1_4seq1.xml · nonDerivative · entry 1

Dexcel Pharma Technologies Ltd. · CIK 0001720007 · 10% owner

Oren Dan · CIK 0001636701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,494,820

F1 · shares: Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.

F2 · price: The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.

F4 · price: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F1 · acquired: Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.

SEC source: 0001104659-20-094753 · tm2027548d2_4.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 447,927

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-20-094755 · tm2027548d3_4.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 246,146

F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-20-094751 · tm2027548d1_4.xml · derivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,656

Underlying: Common Stock · 122,656 shares

Expires 2030-08-11

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025 and (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028.

SEC source: 0001104659-20-095623 · tm2027654-1_4a.xml · nonDerivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 447,927

F1 · security: The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares.

F2 · security: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F2 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F3 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-20-095626 · tm2027654-2_4a.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP and CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 246,146

F1 · security: The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares.

F2 · security: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F2 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

F3 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

SEC source: 0001104659-20-082116 · tm2024387d2_4.xml · derivative · entry 1

Hayon Yael · CIK 0001817121 · VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,771

Underlying: Common Stock · 129,771 shares

Expires 2030-07-05

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-070906 · tm2022027d1_4.xml · derivative · entry 1

Almon Einat Brill · CIK 0001385116 · SVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,995

Underlying: Common Stock · 196,995 shares

Expires 2030-06-07

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025.

SEC source: 0001104659-20-045926 · tm2015785d1_4.xml · nonDerivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.39 to $2.53. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-20-011315 · tm205452-3_4.xml · derivative · entry 1

Bronfeld Zeev · CIK 0001298522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2030-02-03

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-005972 · tm205452-6_4.xml · derivative · entry 1

Granot David · CIK 0001551620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-01-20

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-005971 · tm205452-5_4.xml · derivative · entry 1

Bar-Shalev Amos · CIK 0001385113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-01-20

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-005970 · tm205452-4_4.xml · derivative · entry 1

Schwartz Aharon · CIK 0001625184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-01-20

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-005967 · tm205452-2_4.xml · derivative · entry 1

Boudes Pol F · CIK 0001454771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-01-20

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001104659-20-005965 · tm205452-1_4.xml · derivative · entry 1

Melincoff Gwen A · CIK 0001614890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-01-20

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001144204-19-045806 · tv530009_4.xml · derivative · entry 1

Rubin Eyal · CIK 0001721411 · Sr. VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2029-09-22

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001144204-19-033654 · tv524753_4.xml · derivative · entry 1

Bashan Dror · CIK 0001781450 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires 2029-06-30

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

SEC source: 0001144204-18-049524 · tv502884_4.xml · derivative · entry 1

Maimon Yossi · CIK 0001385115 · VP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2028-09-13

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

SEC source: 0001144204-18-049522 · tv502883_4.xml · derivative · entry 1

Almon Einat Brill · CIK 0001385116 · SVP, Product Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2028-09-13

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

SEC source: 0001144204-18-049521 · tv502882_4.xml · derivative · entry 1

Naos Yaron · CIK 0001742727 · Sr. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2028-09-13

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 115,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

SEC source: 0001144204-18-049517 · tv502881_4.xml · derivative · entry 1

Manor Moshe · CIK 0001623532 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300,000

Underlying: Common Stock · 1,300,000 shares

Expires 2028-09-13

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include options to purchase 900,000 shares of common stock at an exercise price equal to $2.37 per share that expire on September 29, 2024.

SEC source: 0001144204-18-049515 · tv502880_4.xml · derivative · entry 1

Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2028-09-13

F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.

F2 · balance_after: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

SEC source: 0001144204-17-027803 · v467168_4.xml · nonDerivative · entry 1

Manor Moshe · CIK 0001623532 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

SEC source: 0001354488-16-008627 · issuerdirect_section16.xml · nonDerivative · entry 1

Camber Capital Management LLC · CIK 0001444043 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,775,000

F1 · ownership.nature: Securities reported herein for Camber Capital Management LLC (the "LLC" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Master Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 21, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.

F2 · ownership.nature: Of the securities reported for this transaction, 2,413,466 shares of Common Stock were sold for the account of the Master Fund, 16,998 shares of Common Stock were sold for the account of the Fund, and 69,536 shares of Common Stock were sold for the account of the Managed Account.

F3 · ownership.nature: As of the closing of trading on December 06, 2016, 10,402,037 shares of Common Stock were held for the account of the Master Fund, 73,262 shares of Common Stock were held for the account of the Fund, and 299,701 shares of Common Stock were held for the account of the Managed Account.

SEC source: 0001144204-16-124284 · v448888_4.xml · derivative · entry 3

Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 122,162 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents exercise of all stock underlying the derivative security.

F3 · derivative.expiration_date: Represents exercise of all stock underlying the derivative security.

F4 · balance_after: Does not include options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

SEC source: 0001144204-16-124284 · v448888_4.xml · nonDerivative · entry 1

Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.